Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer - PubMed (original) (raw)
Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer
J Kavanagh et al. J Clin Oncol. 1995 Jul.
Abstract
Purpose: To determine the activity of carboplatin in patients with ovarian cancer who progressed on taxane (paclitaxel or docetaxel) therapy.
Patients and methods: Thirty-three patients with ovarian cancers refractory to platinum and taxane therapy were treated with single-agent carboplatin reinduction once the disease progressed on a taxane. The starting dose of carboplatin was 300 mg/m2 at 28-day intervals.
Results: Patients were a median age of 56 years (range, 31 to 80), had a median Zubrod performance status of 1 (range, 0 to 2) and had received a median of three prior chemotherapy regimens (range, two to eight) and one pretaxane platinum regimen (range, one to three). Twenty-six patients had a platinum-free interval of at least 12 months at the time of posttaxane re-treatment with carboplatin. There were seven of 33 (21%) partial responses, with a median duration of 7+ months (range, 2+ to 12+). Responses were noted only in patients with at least a 12-month platinum-free interval and an initial sensitivity to a taxane. The therapy was well tolerated and neurotoxicity was absent.
Conclusion: A subset of patients with platinum-refractory disease that initially responded to a taxane and who eventually have a platinum-free interval of at least 1 year may respond to carboplatin reinduction. This finding may be secondary to paclitaxel or docetaxel therapy that leads to the reversal of platinum resistance, or the prolonged platinum-free interval permits the loss of resistance to platinum by the tumor. Carboplatin reinduction should be considered in the treatment of patients whose ovarian cancer progresses after an initial sensitivity to a taxane and who had a prolonged platinum-free interval.
Similar articles
- Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT. Chambers SK, et al. Clin Cancer Res. 1996 Oct;2(10):1693-7. Clin Cancer Res. 1996. PMID: 9816118 Clinical Trial. - Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?
Noronha V, Patil V, Joshi A, Muddu V, Bhattacharjee A, Juvekar S, Arya S, Chaturvedi P, Chaukar D, Pai PS, Dcruz AK, Prabhash K. Noronha V, et al. Indian J Cancer. 2015 Jan-Mar;52(1):70-3. doi: 10.4103/0019-509X.175604. Indian J Cancer. 2015. PMID: 26837979 - Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, Hakes T. Francis P, et al. J Clin Oncol. 1994 Nov;12(11):2301-8. doi: 10.1200/JCO.1994.12.11.2301. J Clin Oncol. 1994. PMID: 7964944 Clinical Trial. - Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review. - Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N. Katsumata N. Br J Cancer. 2003 Dec;89 Suppl 3(Suppl 3):S9-S15. doi: 10.1038/sj.bjc.6601495. Br J Cancer. 2003. PMID: 14661041 Free PMC article. Review.
Cited by
- Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM. Lampert EJ, et al. Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23. Oncotarget. 2019. PMID: 31080557 Free PMC article. - Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
Luvero D, Milani A, Ledermann JA. Luvero D, et al. Ther Adv Med Oncol. 2014 Sep;6(5):229-39. doi: 10.1177/1758834014544121. Ther Adv Med Oncol. 2014. PMID: 25342990 Free PMC article. Review. - Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.
Zou R, Jiang Q, Luo X, Chen M, Yuan L, Yao L. Zou R, et al. World J Surg Oncol. 2023 Nov 30;21(1):375. doi: 10.1186/s12957-023-03230-3. World J Surg Oncol. 2023. PMID: 38037085 Free PMC article. - Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
Laskey RA, Richard SD, Smith AL, Lin JF, Beck TL, Lesnock JL, Kelley JL 3rd, Olawaiye AB, Sukumvanich P, Krivak TC. Laskey RA, et al. Onco Targets Ther. 2014 Mar 21;7:469-76. doi: 10.2147/OTT.S57425. eCollection 2014. Onco Targets Ther. 2014. PMID: 24711703 Free PMC article. - INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical